Status:
COMPLETED
A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels
Lead Sponsor:
Pfizer
Conditions:
Cardiovascular Disease
Cerebrovascular Accident
Eligibility:
All Genders
35-75 years
Phase:
PHASE4
Brief Summary
The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum...
Eligibility Criteria
Inclusion
- Men and women age 35-75 who have evident CHD
Exclusion
- Known hypersensitivity to HMG CO-A reductase therapy, liver disease, evidence of secondary hyperlipidemia
Key Trial Info
Start Date :
April 1 1998
Trial Type :
INTERVENTIONAL
End Date :
August 1 2004
Estimated Enrollment :
8600 Patients enrolled
Trial Details
Trial ID
NCT00327691
Start Date
April 1 1998
End Date
August 1 2004
Last Update
May 3 2007
Active Locations (314)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Alabaster, Alabama, United States, 35007
2
Pfizer Investigational Site
Birmingham, Alabama, United States, 35205-4785
3
Pfizer Investigational Site
Birmingham, Alabama, United States, 35213
4
Pfizer Investigational Site
Birmingham, Alabama, United States, 35294-2041